Navigation Links
Arena Pharmaceuticals Announces Fourth Quarter and Full Year 2010 Financial Results and Reviews Recent Developments
Date:3/11/2011

he histamine H3 receptor for the treatment of narcolepsy with cataplexy. In this randomized, double-blind, placebo-controlled trial in 24 healthy volunteers, APD916 demonstrated dose-proportional pharmacokinetic exposure over the tested dose range.

Outlook for 2011Arena expects to use cash and cash equivalents of approximately $78 to $84 million for its operating activities and interest expense in 2011, and approximately $2 million for capital expenditures. In January 2011, Arena prepaid the $20 million payment that was due to Deerfield in July 2011. Assuming no additional capital from collaborators, investors or other sources, Arena would expect to end 2011 with approximately $45 million to $51 million.

Scheduled Earnings Call Arena will host both a conference call and webcast to discuss the fourth quarter and full year 2010 financial results and to provide a business and financial update today, Friday, March 11, 2011, at 8:30 a.m. Eastern Time (5:30 a.m. Pacific Time).

The conference call may be accessed by dialing 877.643.7155 for domestic callers and 914.495.8552 for international callers. Please specify to the operator that you would like to join the "Arena Pharmaceuticals' Fourth Quarter and Full Year 2010 Financial Results Call." The conference call will be webcast live under the investor relations section of Arena's website at www.arenapharm.com, and will be archived there for 30 days following the call. Please connect to Arena's website several minutes prior to the start of the broadcast to ensure adequate time for any software download that may be necessary.

About Arena PharmaceuticalsArena is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing oral drugs that target G protein-coupled receptors, an important class of validated drug targets, in four major therapeutic areas: cardiovascular, central nervous system, inflammato
'/>"/>

SOURCE Arena Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Arena Pharmaceuticals to Present at Four Upcoming Investor Conferences
2. Arena Pharmaceuticals Announces Positive Phase 2 Clinical Trial Results of APD125 for the Treatment of Insomnia
3. Arena Pharmaceuticals Announces APD668 Initial Clinical Study Results Suggest Glucose-Dependent Insulinotropic Receptors May Improve Glucose Control in Patients With Type 2 Diabetes
4. Arena Pharmaceuticals Announces Positive Phase 1a Clinical Trial Results of APD791 for the Treatment of Arterial Thrombosis and Initiates Phase 1b Clinical Trial
5. Arena Pharmaceuticals Initiates Phase 2b Clinical Trial of APD125 for the Treatment of Insomnia
6. Arena Pharmaceuticals, Inc. Announces Initiation of Phase 1 Clinical Trial of Drug Candidate Under Partnership with Taisho Pharmaceutical Co., Ltd.
7. Arena Pharmaceuticals Presented Positive Phase 2a Clinical Trial Results of APD125 for the Treatment of Insomnia at 22nd Annual Meeting of the Associated Professional Sleep Societies
8. Arena Pharmaceuticals Announces Positive Phase 1b Clinical Trial Results of APD791 for the Treatment of Arterial Thrombosis
9. Critical Pharmaceuticals Enter Sustained Release hGH Arena
10. Arena Pharmaceuticals Announces Preliminary Results of Phase 2b Clinical Trial of APD125 for the Treatment of Insomnia
11. Arena Pharmaceuticals Announces Initiation of Phase 1 Clinical Trial of Type 2 Diabetes Drug Candidate in Partnership with Ortho-McNeil-Janssen Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/26/2014)... Aug. 26, 2014  When it comes to diabetes supplies, ... relevance. But Timesulin happens to answer a real medical ... pen on the market, Timesulin shows how long it,s ... preventing from missed or double insulin doses. Very easy ... back on the insulin pen after an injection. There ...
(Date:8/26/2014)... 2014  Ethicon* is introducing three new endocutter and ... of bariatric procedures such as sleeve gastrectomy and gastric ... the 19th World Congress of International Federation for the ... Ethicon is featuring the new ECHELON FLEX ™ ... G2 Articulating Tissue Sealer alongside the HARMONIC ACE ® ...
(Date:8/26/2014)... , Aug. 26, 2014  Avanir Pharmaceuticals, Inc. ... enrollment of the first patient into a phase ... tolerability of AVP-786 for the adjunctive treatment of ... investigational drug consisting of a combination of deuterium ... "There are millions of people with MDD who ...
Breaking Medicine Technology:Montméd obtains reimbursement of Timesulin, the smart insulin pen timer cap, by major insurance companies in Canada 2Ethicon Expands Bariatric Surgery Portfolio; Unveils "Evidence Corner" At IFSO To Address Obesity And Metabolic Diseases 2Ethicon Expands Bariatric Surgery Portfolio; Unveils "Evidence Corner" At IFSO To Address Obesity And Metabolic Diseases 3Ethicon Expands Bariatric Surgery Portfolio; Unveils "Evidence Corner" At IFSO To Address Obesity And Metabolic Diseases 4Ethicon Expands Bariatric Surgery Portfolio; Unveils "Evidence Corner" At IFSO To Address Obesity And Metabolic Diseases 5Ethicon Expands Bariatric Surgery Portfolio; Unveils "Evidence Corner" At IFSO To Address Obesity And Metabolic Diseases 6Avanir Pharmaceuticals Announces Initiation of Phase II Study of AVP-786 for the Adjunctive Treatment of Major Depressive Disorder 2Avanir Pharmaceuticals Announces Initiation of Phase II Study of AVP-786 for the Adjunctive Treatment of Major Depressive Disorder 3Avanir Pharmaceuticals Announces Initiation of Phase II Study of AVP-786 for the Adjunctive Treatment of Major Depressive Disorder 4Avanir Pharmaceuticals Announces Initiation of Phase II Study of AVP-786 for the Adjunctive Treatment of Major Depressive Disorder 5Avanir Pharmaceuticals Announces Initiation of Phase II Study of AVP-786 for the Adjunctive Treatment of Major Depressive Disorder 6
... Nov. 10, 2011 Shands Jacksonville Medical ... Masimo (NASDAQ: MASI ) ... Center to Masimo rainbow® SET Pulse CO-Oximetry™ technology for ... acute care hospital, which also operates one of the ...
... 2011 Cancer Support Community in collaboration with Center ... to host a workshop from the popular Frankly ... workshop will address the topic of breast reconstruction options, ... MD, and a panel of breast cancer survivors. The ...
Cached Medicine Technology:Shands Jacksonville Medical Center Converts to Masimo rainbow SET for State-of-the-Art Noninvasive Patient Monitoring Capabilities 2Shands Jacksonville Medical Center Converts to Masimo rainbow SET for State-of-the-Art Noninvasive Patient Monitoring Capabilities 3Shands Jacksonville Medical Center Converts to Masimo rainbow SET for State-of-the-Art Noninvasive Patient Monitoring Capabilities 4Shands Jacksonville Medical Center Converts to Masimo rainbow SET for State-of-the-Art Noninvasive Patient Monitoring Capabilities 5Shands Jacksonville Medical Center Converts to Masimo rainbow SET for State-of-the-Art Noninvasive Patient Monitoring Capabilities 6Cancer Support Community in Collaboration with the Center for Breast Health at Washington Hospital Center Hosts Free Frankly Speaking About Cancer: Spotlight on Breast Reconstruction Workshop on Thursday, November 10 2Cancer Support Community in Collaboration with the Center for Breast Health at Washington Hospital Center Hosts Free Frankly Speaking About Cancer: Spotlight on Breast Reconstruction Workshop on Thursday, November 10 3
(Date:8/27/2014)... Neil Haley, the Total Tutor host of the Simply ... about the importance of capacity to grow a business. , ... and is now a 5 Star Ambassador, Vi Millionaire, and ... titled "The Playful and Powerful Warrior Within You!" and holds ... out for over 1000 days straight. He is also ...
(Date:8/27/2014)... 27, 2014 Overcoming a turbulent past which ... his niche. The Women’s Radio Network, WRNW1, has recently signed ... support and dedication to the WRNW1 family. KC states, “it ... such a positive atmosphere.” After KC Armstrong publicly announced his ... the Howard Stern show, “Howard 100 News,” have decided to ...
(Date:8/27/2014)... A recently published study ... time in correcting coagulopathy to prevent permanent injury or ... anticoagulants and examines medical conditions alleged to be caused ... anticoagulants have been approved by the FDA to reduce ... also known to affect the consistency of the anticoagulation ...
(Date:8/27/2014)... August 27, 2014 The use of ... of life and may eliminate the need for blood ... a recent AllMed webinar, Dr. Zanhua Yi, board certified ... to determining medical necessity of erythropoiesis-stimulating agents (ESAs) in ... , The U.S. Food and Drug Administration (FDA) has ...
(Date:8/27/2014)... Frederick, MD (PRWEB) August 27, 2014 ... and family-friendly practices as the “Most Creative Workplace” ... Frederick County Best Places to Work Awards. , ... the annual event is a joint partnership between ... Department of Economic Development, Frederick County Business Development ...
Breaking Medicine News(10 mins):Health News:Vi Millioniare GJ Reynolds Discusses The Importance of Capacity to Grow a Business on the Simply G Radio Show, a Division of the Simply G Media Network 2Health News:Vi Millioniare GJ Reynolds Discusses The Importance of Capacity to Grow a Business on the Simply G Radio Show, a Division of the Simply G Media Network 3Health News:The Women's Radio Network, WRNW1, Signs KC Armstrong to a Multi-Million Dollar Contract 2Health News:Flood Law Group Comments on Recent AAICH Study 2Health News:AllMed Webinar Helps Health Plans Determine Medical Necessity Of ESAs In The Treatment Of Chronic Kidney Disease 2Health News:AllMed Webinar Helps Health Plans Determine Medical Necessity Of ESAs In The Treatment Of Chronic Kidney Disease 3Health News:iHire Named Most Creative Workplace in Frederick, MD 2
... tall extremes may put added pressure on joints, study ... Common genetic variants associated with osteoarthritis may also play ... a U.S.-European study. , The findings, which included an ... are exciting for a number of reasons, said ...
... Childrens Hospital has been named the national lead ... the German-manufactured pediatric heart pump called Berlin Heart ... Fraser, Jr., MD, chief of pediatric and congenital ... E. DeBakey Department of Surgery at Baylor College ...
... transplanted because of the generosity of,donors and their families, ... Perkiomenville, 2007 was a year that brought the greatest ... for a multi-organ,transplant, her parents Shane and Jill watched ... a miracle., That wish was answered just three ...
... today that the United States Food and,Drug Administration ... first LDL cholesterol lowering medication also indicated for,improving ... mellitus (DM) in,combination with metformin, sulfonylureas, or insulin, ... with other anti-diabetic agents., The ADA estimates ...
... Joined by New York City Mayor,Michael Bloomberg, Lance ... today discussed Lance,s request to the Surgeons General,Collective ... "This year alone, 1.4 million Americans are ... likely lose their lives to the disease," said,Lance ...
... the San Diego Supercomputer Center and other parts of ... in Parkinsons Disease, fusion energy and climate change - ... Energy (DOE) as part of its 2008 Innovative and ... , In total, the DOEs Office of Science awarded ...
Cached Medicine News:Health News:Genes Linked to Height Also Tied to Osteoarthritis Risk 2Health News:National study will look at German-made heart pump for children needing heart transplants 2Health News:National study will look at German-made heart pump for children needing heart transplants 3Health News:Gift of Life Celebrates Saving Lives and Setting Records in 2007 2Health News:Gift of Life Celebrates Saving Lives and Setting Records in 2007 3Health News:MultiVu Video Feed: WELCHOL (R) (COLESEVELAM HCL) RECEIVES FDA APPROVAL FOR GLUCOSE CONTROL IN ADULTS WITH TYPE 2 DIABETES MELITUS 2Health News:Lance Armstrong and 17th U.S. Surgeon General Carmona Announce National Call to Action in the War Against Cancer 2Health News:Lance Armstrong and 17th U.S. Surgeon General Carmona Announce National Call to Action in the War Against Cancer 3Health News:DOE awards supercomputing time to UCSD, SDSC researchers 2Health News:DOE awards supercomputing time to UCSD, SDSC researchers 3
... AIA-1800 is the newest and most advanced ... The AIA-1800 launches with a full menu ... thyroid, reproductive, cardiac, and anemia assays. ,The ... bar-coded primary tube sampling, auto dilution, auto ...
... Tosoh, innovators of automated random access immunoassay testing, ... builds on the proven reliability of Tosohs original ... rapid result processing, and continuous process operation., Test ... T4 FT3 FT4 T-Uptake ...
The FastPack system is a state of the art, lab quality immunoassay system designed for rapid results. The FastPack system delivers lab-quality sensitivity at a fraction of the cost of laboratory....
... Vitros ECi brings true automation and ... testing. Highly sensitive assays for thyroid, ... bone metabolism testing are currently available, ... The Vitros ECi can simultaneously process ...
Medicine Products: